11.05.10
Turku – Finnish Biotie Therapies Corp. confirmed that its oral phosphodiesterase 4 inhibitor ELB353 has proven safe and pharmacologically active in a Phase I study. Pharmacokinetic data point to the suitability of ELB353 for a once-daily dosing regimen.
